NASDAQ:ASLN - ASLAN PHARMACEU/ADR Stock Price, Forecast & News

ASLAN PHARMACEU/ADR trades on the NASDAQ under the ticker symbol "ASLN."

ASLAN PHARMACEU/ADR (NASDAQ:ASLN) announced its earnings results on Thursday, October, 31st. The company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.22) by $0.19. View ASLAN PHARMACEU/ADR's Earnings History.

ASLAN PHARMACEU/ADR is scheduled to release their next quarterly earnings announcement on Friday, March 27th 2020. View Earnings Estimates for ASLAN PHARMACEU/ADR.

3 Wall Street analysts have issued 1 year price targets for ASLAN PHARMACEU/ADR's shares. Their forecasts range from $5.00 to $8.00. On average, they expect ASLAN PHARMACEU/ADR's stock price to reach $6.50 in the next twelve months. This suggests a possible upside of 147.1% from the stock's current price. View Analyst Price Targets for ASLAN PHARMACEU/ADR.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ASLAN PHARMACEU/ADR in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ASLAN PHARMACEU/ADR.

Press coverage about ASLN stock has been trending extremely negative this week, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. ASLAN PHARMACEU/ADR earned a news sentiment score of -5.0 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for ASLAN PHARMACEU/ADR.

Some companies that are related to ASLAN PHARMACEU/ADR include Minerva Neurosciences (NERV), Stemline Therapeutics (STML), Puma Biotechnology (PBYI), Galera Therapeutics (GRTX), CytomX Therapeutics (CTMX), INDIVIOR PLC/S (INVVY), Satsuma Pharmaceuticals (STSA), Albireo Pharma (ALBO), MannKind (MNKD), VBI Vaccines (VBIV), Kalvista Pharmaceuticals (KALV), BioXcel Therapeutics (BTAI), MediciNova (MNOV), Evofem Biosciences (EVFM) and Geron (GERN).

Based on aggregate information from My MarketBeat watchlists, some companies that other ASLAN PHARMACEU/ADR investors own include Sierra Oncology (SRRA), Onconova Therapeutics (ONTX), Opko Health (OPK), Cassava Sciences (SAVA), AcelRx Pharmaceuticals (ACRX), Allena Pharmaceuticals (ALNA), Cidara Therapeutics (CDTX), Sorrento Therapeutics (SRNE), Depomed (ASRT) and Actinium Pharmaceuticals (ATNM).

(ASLN) raised $60 million in an IPO on Friday, May 4th 2018. The company issued 7,500,000 shares at a price of $8.05 per share. Leerink Partners and Piper Jaffray served as the underwriters for the IPO and BTIG, H.C. Wainwright and CLSA were co-managers.

Shares of ASLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ASLN stock can currently be purchased for approximately $2.63.

ASLAN PHARMACEU/ADR has a market capitalization of $84.29 million. The company earns $-42,190,000.00 in net income (profit) each year or ($1.40) on an earnings per share basis. View Additional Information About ASLAN PHARMACEU/ADR.

The official website for ASLAN PHARMACEU/ADR is http://aslanpharma.com/.

ASLAN PHARMACEU/ADR's mailing address is 83 CLEMENCEAU AVENUE 12-03 UE SQUARE, SINGAPORE U0, 239920. The company can be reached via phone at 65-6222-4235 or via email at [email protected]